MedPath

Treatment of NAFLD with N-Acetylsyctein, Pioglitazon and Metformi

Phase 3
Conditions
on Alcoholic Fatty Liver Disease.
Nonalcoholic steatohepatitis
Registration Number
IRCT201309188308N3
Lead Sponsor
Vice Chancellor for Research and Technology University of Medical Sciences of Hamedan
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

1) Elevated liver enzymes > 1.5 times
2) Sonographic diagnosis of NAFLD (Grade 1 and more)

Exclusion criteria:
1) Viral hepatitis
2) Alcoholic liver disease
3) Autoimmune liver disease
4) Hepatotoxic drug use in the past 6 month
5) Systemic illness
6) Metabolic liver disease
7) Active drug abuse
8) Pregnancy
9) Diabetes mellitus

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
iver enzymes. Timepoint: two month. Method of measurement: Labratory.
Secondary Outcome Measures
NameTimeMethod
Grading of Steatosis. Timepoint: two month. Method of measurement: Sonography.
© Copyright 2025. All Rights Reserved by MedPath